Benzinga | Aug 5, 2020 04:04PM EDT

Fate Therapeutics Q2 EPS $(0.35) Misses $(0.27) Estimate, Sales $5.37M Miss $13.23M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 2.78 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $5.37 million which missed the analyst consensus estimate of $13.23 million by 59.45 percent. This is a 90.45 percent increase over sales of $2.82 million the same period last year.